Lipid-lowering effect and efficacy after switching to etravirine in hiv-infected patients with intolerance to suppressive HAART

HIV Clinical Trials

Volumn 14, Issue 1, 2013, Pages 1-9

  Casado, José ^a   De Los Santos, Ignacio ^b   Del Palacio, María ^a   García Fraile, Lucio ^b   Pérez Elías, María ^a   Sanz, Jesús ^b   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

etravirine; lipids; metabolism; NNRTIs; simplification

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; RALTEGRAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; LIPODYSTROPHY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CARBAMATES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPIDS; LOPINAVIR; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORGANOPHOSPHATES; PYRIDAZINES; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SPAIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84873348360     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1401-1     Document Type: Article

References (28)

1. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118:198-210
2. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289: 2978-2982 (Pubitemid 37430100)
3. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specifi c antiretroviral agents, and treatment regimens. J Acquir Immune Defi c Syndr. 2007;45:34-42 (Pubitemid 46684441)
4. Fisac C, Fumero E, Crespo M, et al. Metabolic benefi ts 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917-925 (Pubitemid 40834934)
5. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profi le in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383-1389 (Pubitemid 34722070)
6. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodefi ciency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34:504-510 (Pubitemid 34112272)
7. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805-810 (Pubitemid 29224582)
8. Negredo E, Ribalta J, Ferrer E, et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV infected patients. AIDS. 2004;18:819-821 (Pubitemid 38535014)
9. Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profi les in antiretroviral therapy naïve patients infected with HIV-1. PLoS Med. 2004;1:e19
10. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of fi rst line antiretroviral therapy with regimens including nevirapine, efavirenz or both drugs, plus stavudine and lamivudine: a randomized open label trial, the 2NN study. Lancet. 2004;363:1253-1263 (Pubitemid 38496486)
11. Riddler SA, Haubrich R, DiRienzo G, et al. Class sparing regimens for initial treatment of HIV-1 infection. N Eng J Med. 2008;358:2095-2106 (Pubitemid 351679596)
12. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment experienced HIV infected patients: pooled 48 weeks analysis of two randomized controlled trials. AIDS. 2009;23:2289-2300
13. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fi nal report. Circulation. 2002;106:3143-3421
14. National Health Institute. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 2004. http://www.niaid.nih.gov/ LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf
15. Dobiasova M, Frohlich J. The plasma parameter log (TC/HDL-c) as an atherogenic index: correlation with lipoprotein particle size and esterifi cation rate in apoBlipoprotein- depleted plasma. Clin Biochem. 2001;34: 583-588 (Pubitemid 34014853)
16. Raffi F, Bonnet B, Ferré V, et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodefi ciency virus type 1 RNA. Clin Infect Dis. 2000;31:1274-1278 (Pubitemid 32295461)
17. Parienti JJ, Massari V, Rey D, et al. Efavirenz to nevirapine switch in HIV-1 infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis. 2007;45:263-266 (Pubitemid 47041021)
18. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Effi cacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48 weeks results. Clin Infect Dis. 2007;44:1484-1492 (Pubitemid 46801594)
19. Rubio R, Serrano O, Carmena J, et al. Effect of simplifi cation from protease inhibitors to boosted atazanavir-based regimen in real life conditions. HIV Med. 2010;11:545-553
20. Martinez E, Larrousse M, Llibre J, et al; for the SPIRAL Study Group. Substitution of raltegravir for ritonavirboosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697-1707
21. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir- ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407
22. Squires KE, Young B, Dejesus E, et al. Similar effi cacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24:2019-2027
23. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment- naive, HIV type 1-infected subjects over 48 weeks [published online ahead of print April 2, 2012]. AIDS Res Human Retroviruses. 2012; 28
24. Fatkenheuer G, Duvivier C, Rieger A, et al. Lipid profi les for etravirine versus efavirenz in treatment naïve patients in the randomized double blind SENSE trial. J Antimicrob Chemother. 2012;67:685-690
25. Waters L, Fisher M, Winston A, et al. A phase IV, doubleblind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS. 2012;25: 65-71
26. Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS. 2011;25:57-63
27. Falcone EL, Mangili A, Skinner S, et al. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther. 2011;16:1-8
28. Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25:1497-1504.